Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MIC Banks On PET/CT Services To Offset Siemens, GE Device Leasing Costs

This article was originally published in The Gray Sheet

Executive Summary

Molecular Imaging Corp. plans to refocus its business strategy on providing integrated PET/CT imaging services to its hospital, physician group and diagnostic imaging center customers, rather than concentrating on PET services alone

You may also be interested in...



PET Groups Carp On CMS Coverage Policy, National Coverage Decision Delay

CMS' cautious approach to covering positron emission tomography indications has spurred criticism among the PET industry, which seeks to accelerate reimbursement to drive the technology's adoption

MR/CT Pipeline Intact After GEMS Reshuffling: Ultrasound Ablation In View

GE Medical Systems will integrate InSightec's ExAblate ultrasound ablation technology with its existing Signa MRI scanners for shipment upon PMA approval, projected by mid-2004

News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR

This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT021241

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel